dalteparin has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 6 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Children with acute lymphoblastic leukemia (ALL) have a substantial risk for thromboembolism (TE) that is related to L-asparaginase-induced antithrombin (AT) deficiency and placement of central venous lines." | 2.73 | Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. ( Hager, J; Klein-Franke, A; Kropshofer, G; Meister, B; Strasak, AM; Streif, W, 2008) |
| "Forty-one consecutive children with acute lymphoblastic leukemia (ALL) received prophylaxis therapy with the low molecular weight heparin (LMWH) enoxaparin during L-asparaginase treatment." | 2.70 | Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. ( Ben Barak, A; Brenner, B; Elhasid, R; Lanir, N; Levin, C; Postovsky, S; Sharon, R; Weyl Ben Arush, M, 2001) |
| "Eighteen patients were found to have a genetic predisposition for TE, all of them received prophylactic LMWH." | 1.36 | Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. ( Ben Arush, MW; Brenner, B; Elhasid, R; Harlev, D; Sarig, G; Zaidman, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mazzoleni, S | 1 |
| Putti, MC | 1 |
| Simioni, P | 1 |
| Sainati, L | 1 |
| Tormene, D | 1 |
| Manara, R | 1 |
| Carli, M | 1 |
| Malhotra, P | 1 |
| Jain, S | 1 |
| Kapoor, G | 1 |
| Mitchell, L | 1 |
| Lambers, M | 1 |
| Flege, S | 1 |
| Kenet, G | 1 |
| Li-Thiao-Te, V | 1 |
| Holzhauer, S | 1 |
| Bidlingmaier, C | 1 |
| Frühwald, MC | 1 |
| Heller, C | 1 |
| Schmidt, W | 1 |
| Pautard, B | 1 |
| Nowak-Göttl, U | 1 |
| Harlev, D | 1 |
| Zaidman, I | 1 |
| Sarig, G | 1 |
| Ben Arush, MW | 1 |
| Brenner, B | 2 |
| Elhasid, R | 2 |
| Meister, B | 1 |
| Kropshofer, G | 1 |
| Klein-Franke, A | 1 |
| Strasak, AM | 1 |
| Hager, J | 1 |
| Streif, W | 1 |
| Lanir, N | 1 |
| Sharon, R | 1 |
| Weyl Ben Arush, M | 1 |
| Levin, C | 1 |
| Postovsky, S | 1 |
| Ben Barak, A | 1 |
2 trials available for dalteparin and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Topics: Adolescent; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Antithrombins; Asparagin | 2008 |
Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
Topics: Adolescent; Anticoagulants; Antineoplastic Agents; Asparaginase; Blood Coagulation Factors; Child; C | 2001 |
4 other studies available for dalteparin and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant: a case report and review of the literature.
Topics: Activated Protein C Resistance; Amino Acid Substitution; Brain; Child, Preschool; Fibrinolytic Agent | 2005 |
Symptomatic Cerebral Sinovenous Thrombosis Associated With L-Asparaginase In Children With Acute Lymphoblastic Leukemia: A Single Institution Experience Over 17 Years.
Topics: Adolescent; Anticoagulants; Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Enoxaparin | 2018 |
Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.
Topics: Adolescent; Anticoagulants; Asparaginase; Catheterization, Central Venous; Child; Child, Preschool; | 2010 |
Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.
Topics: Adolescent; Anticoagulants; Asparaginase; Child; Child, Preschool; Enoxaparin; Female; Genetic Predi | 2010 |